Navigation Links
Seaside publishes research supporting disease-modifying potential of STX209 for fragile X syndrome
Date:9/19/2012

CAMBRIDGE, Mass., (Embargoed until September 19, 2012, 2:00 PM US Eastern Time) Seaside Therapeutics today announced the publication of two papers in Science Translational Medicine, supporting its lead candidate, STX209 (arbaclofen), for the treatment of fragile X syndrome (FXS). The works presented highlight STX209 as a potential disease-modifying drug in preclinical studies, with improvement in social function in a clinical trial of patients with FXS.

"In preclinical results, we demonstrate that STX209 treatment corrects core aspects of FXS pathophysiology in the fragile X mouse model, leading us to conclude that STX209 is a disease-modifying drug with the potential to significantly improve the lives of patients with fragile X," said Randall Carpenter, MD, President and Chief Executive Officer of Seaside Therapeutics. "In fact, in our Phase 2 clinical trial, we observed statistically significant improvements in social avoidance, a core symptom of fragile X syndrome that is characterized by behaviors such as preference to be alone and being withdrawn or isolated. Social avoidance is also a core symptom of autism spectrum disorders, suggesting STX209 could have a positive effect in this larger patient population. Together, these results support our continued development of STX209, which is currently enrolling patients in a Phase 3 study in fragile X syndrome and recently completed enrollment in a Phase 2b study in autism spectrum disorders."

"There are currently no FDA approved therapeutics that address the core symptoms of fragile X syndrome, leaving patients and their caregivers with limited treatment options," said Elizabeth Berry-Kravis, MD, PhD, Professor of Pediatrics, Neurology, and Biochemistry at Rush University Medical Center in Chicago, and the lead author of the paper on the Phase 2 study results. "We are very excited about the clinically meaningful improvements in social impairment observed to date in patients receiving
'/>"/>

Contact: Kari Watson
kwatson@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
2. Nonprofit Consortium Publishes Review of Skullcap Adulteration
3. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
4. American Botanical Council Publishes a History of Adulteration
5. Stanford faculty awarded $2.2 million for innovative energy research
6. Electronics without current: Finnish team to research the future of nanoelectronics
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
9. Penn researchers make first all-optical nanowire switch
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... German . , They have been used as ... they are making rapid inroads in high performance applications: CMOS ... and digital cameras. The automotive industry, for instance, has discovered ... them in driver assistance systems from parking aids and ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) today announced ... of its common stock and warrants to purchase common stock in ... and there can be no assurance as to whether or when ... or terms of the offering. Roth Capital Partners is ...
... 23, 2011 Scarguard Labs, LLC, a closely held ... other dermatological problems through the use of multi-technology drugs ... that they have received approval from Health Canada to ... "We are very pleased to gain approval for ...
Cached Biology Technology:UV-transparent coating for image sensors 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... Human Genetics (ASHG) and the National Human Genome ... of Health, have named Katherine D. Blizinsky, PhD, ... newest ASHG/NHGRI Genetics and Public Policy Fellow. The ... Public Policy Fellowship is intended to help early-career ... research policy at a national level. Fellows in ...
(Date:9/2/2014)... team of University of Maryland physicists has published ... say make possible new nanostructures and nanotechnologies with ... quantum computing advances to new sensor development. , ... Nature Communications the Maryland scientists, primary discovery ... nanostructures that uses a connector, or "intermedium," nanoparticle ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2ASHG and NHGRI award genetics and public policy fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3
... June, 2010) SAGE, the world,s fifth leading independent ... the Bulletin of the Atomic Scientists from September ... other experts who had created the atomic bomb as part ... threats to the survival and development of humanity from nuclear ...
... research led by the University of Leicester and published in ... first time the mechanism by which memories are formed. ... found one of the key proteins involved in the process ... to impact drug design to treat Alzheimer,s disease. The ...
... the hon-shimeji mushroom is a delicacy costing up to SEK 8,000 ... of Gothenburg, Sweden, has discovered that this tasty fungus also grows ... of interest in Sweden, and definitely in Japan once these discoveries ... Lyophyllum is a family of many different species ...
Cached Biology News:SAGE to publish the Bulletin of the Atomic Scientists 2Memories are made of this 2Japanese gourmet mushroom found in Sweden 2Japanese gourmet mushroom found in Sweden 3
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 ... from human DNA fragmentation factor (DFF). The sequence of ... - P - K - S - V - K ... - S - P - R - K(18). ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... High Throughput Processing of Microarrays Using the ... Frame multiple slide plate is designed to ... corresponding multi-well incubation chambers in a microplate ... The footprint dimensions meet the standards recommended ...
fully automated system for the processing of microarrays on microscope slides...
Biology Products: